The mortality rate due to COVID-19 in immunocompromised cases is considerably high. Monoclonal antibody (mAb) therapy is essential in managing SARS-CoV-2 infection, especially in immunocompromised cases. The mutation in the spike protein RBD region of the SARS-CoV-2 leads to the substitution of amino acids resulting in an altered ACE2 binding affinity. The mAbs must be tested in-vitro using standard neutralisation assays designed against emerging SARS-CoV-2 variants to estimate the mAb therapy efficacy. Based on already available data on the mAb efficacy for known SARS-CoV-2 variants, it is plausible to draw inferences for other closely related SARS-CoV-2 variants in circulation owing to the similar spike protein RBD amino acid sequence. In this article, we have attempted to analyse the data of mAb efficacy tested against SARS-CoV-2 variants and extrapolate on other emerging omicron sublineages like BA.2.75, BF.7 and BQ.1.